{"id":8855,"date":"2025-10-06T00:30:10","date_gmt":"2025-10-05T21:30:10","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8855"},"modified":"2025-10-06T00:30:10","modified_gmt":"2025-10-05T21:30:10","slug":"vericiguat-in-heart-failure-victoria-vs-victor-esc-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/vericiguat-in-heart-failure-victoria-vs-victor-esc-2025\/","title":{"rendered":"Vericiguat in Heart Failure \u2013 VICTORIA vs VICTOR (ESC 2025)"},"content":{"rendered":"
Vericiguat in Heart Failure \u2013 VICTORIA vs VICTOR (ESC 2025)<\/div>\n
<\/div>\n
1. Background<\/span><\/div>\n
\u2022 Vericiguat: a drug that stimulates soluble guanylate cyclase, tested in HFrEF.<\/span><\/div>\n
\u2022 VICTOR trial (ESC 2025): larger, lower-risk patients, follow-up to VICTORIA trial.<\/span><\/div>\n
2. VICTORIA Trial (2020)<\/span><\/div>\n
\u2022 Enrolled very high-risk HF patients.<\/span><\/div>\n
\u2022 Showed small benefit (~10% event reduction).<\/span><\/div>\n
\u2022 Benefit came mainly from sickest patients.<\/span><\/div>\n
3. VICTOR Trial (2025)<\/span><\/div>\n
\u2022 Larger, lower-risk group; excluded NT-proBNP >6000 (NT-proBNP = heart stress blood test; higher = worse).<\/span><\/div>\n
\u2022 Most on modern therapy \u2013 ARNI, MRA, \u03b2-blocker; fewer SGLT2i.<\/span><\/div>\n
\u2022 Neutral result (no benefit, no harm) \u2013 P\u22480.2.<\/span><\/div>\n
4. Prespecified Analyses (planned in advance)<\/span><\/div>\n
\u2022 Suggested fewer deaths ,but no \u2193 hospitalization.<\/span><\/div>\n
5. Pooled Analysis (combining trials for bigger picture)<\/span><\/div>\n
\u2022 VICTOR + VICTORIA showed reduction in outcomes.<\/span><\/div>\n
\u2022 But effect was same as VICTORIA alone \u2192 no stronger signal despite more patients.<\/span><\/div>\n
6. Biomarkers NT-proBNP (N-terminal pro\u2013B-type Natriuretic Peptide).<\/span><\/div>\n
\u2022 Useful to identify higher-risk patients.<\/span><\/div>\n
\u2022 Rising NT-proBNP = warning for decompensation (sudden worsening of HF).<\/span><\/div>\n
7. Clinical Context<\/span><\/div>\n
\u2022 Vericiguat remains a fifth-line option after the 4 pillars (ARNI, SGLT2i, MRA, \u03b2-blocker).<\/span><\/div>\n
\u2022 May be useful in high-risk or nonresponder patients.<\/span><\/div>\n
8. Takeaway<\/span><\/div>\n
\u2022 VICTOR = neutral trial.<\/span><\/div>\n
\u2022 Vericiguat not standard therapy yet, but may still have a role in select HF patients.<\/span><\/div>\n
<\/div>\n
https:\/\/click.mail.medscape.com\/?qs=81b7b1181eac08975668a57c9882a23bbf5724e40cda3c39129752cb2089cfa12d611364ee3c5b04d1c9d61be16630929af9bf55c201ab93ebac64556085f6e3<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Vericiguat in Heart Failure \u2013 VICTORIA vs VICTOR (ESC 2025) 1. Background \u2022 Vericiguat: a drug that stimulates soluble guanylate cyclase, tested in HFrEF. \u2022 VICTOR trial (ESC 2025): larger, lower-risk patients, follow-up to VICTORIA trial. 2. VICTORIA Trial (2020) \u2022 Enrolled very high-risk HF patients. \u2022 Showed small benefit (~10% event reduction). \u2022 Benefit […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8855","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8855"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8855\/revisions"}],"predecessor-version":[{"id":8856,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8855\/revisions\/8856"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}